FDA approves BWXT's radiopharmaceutical

By AuntMinnie.com staff writers

September 26, 2019 -- U.S. government nuclear components supplier BWX Technologies (BWXT) has received approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (NDA) for a generic version of indium-111 (In-111) oxyquinoline solution.

The NDA was submitted by BWXT's subsidiary, BWXT ITG Canada, for the use of In-111 oxyquinoline for radiolabeling autologous leukocytes. FDA approval allows BWXT to market and distribute In-111 oxyquinoline in the U.S. The radiopharmaceutical also is BWXT ITG Canada's first generic product to come to market.

Copyright © 2019 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking